Skip to main content
Patient-reported outcomes data on health-related quality of life
Navbar Image
Patient-reported outcomes data on health-related quality of life
This site is intended only for US healthcare professionals.

Patient-reported outcomes data on health-related quality of life

SLOWER DECLINE IN HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS RECEIVING COSELA IN STUDY 3

Patient-reported outcomes data were descriptive and exploratory study endpoints in Study 3 to measure the effects of COSELA on health-related quality of life. Outcome measures were not validated in the study population; therefore, no conclusions can be drawn.
  • COSELA was proactively given prior to topotecan3
  • Exploratory endpoint: median time to confirmed deterioration in patient-reported outcomes with COSELA prior to topotecan3,a
  • For severe (Grade 3) or life-threatening (Grade 4) drug hypersensitivity reactions, stop infusion and permanently discontinue COSELA

See the Study Design

Etoposide/carboplatin/atezolizumab regimen arm=placebo + etoposide/carboplatin/atezolizumab.
Topotecan regimen arm=topotecan + placebo.

a
Confirmed deterioration in PROs was defined as a decrease from baseline by a defined threshold for two consecutive visits, ie, change from baseline of ≤3 points for physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing, lung cancer subscale, and fatigue and ≤6 points for Functional Assessment of Cancer Therapy-Lung and ≤7 points for Functional Assessment of Cancer Therapy-General and Functional Assessment of Cancer Therapy-Anemia total scores.3